Topiramate
Product Images NDC 45865-963

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 45865-963). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (963)

Topiramate tablets 50 mg packaging label. The label indicates generic for Topamax, supplied by Cadila Healthcare Ltd. It contains 15 film-coated white round tablets. The label includes lot and expiration details, and it is marked with Medsource Pharmaceuticals as the labeler under NDC 45865-963.*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 01)

Chemical structure diagram depicting the molecule of topiramate, showing its atomic connectivity including oxygen, sulfur, nitrogen, carbon, and hydrogen atoms arranged in a specific 3D configuration with stereochemistry indicated.*

FDA Label Image

Structured Product Formula For Topiramate (A9eed983 Edf1 4f44 A8ec 568a52f03015 02)

A Kaplan-Meier survival plot showing cumulative rates over time until the first seizure for topiramate at 50 mg/day and 400 mg/day. The graph compares two groups of patients (N=234 for 50 mg/day and N=236 for 400 mg/day) over approximately 500 days with cumulative seizure rates on the y-axis and time in days on the x-axis. The plot includes statistical significance (P = 0.0002).*

FDA Label Image

Topiramate Tablets Usp (A9eed983 Edf1 4f44 A8ec 568a52f03015 03)

A bar graph comparing the change from baseline to double-blind phase in average monthly migraine period rate for placebo and three dosages of topiramate (50 mg/day, 100 mg/day, and 200 mg/day) across two studies (Study 10 and Study 11). The graph shows reductions in migraine period rate with increasing topiramate doses, with statistical significance indicated for doses 100 mg/day and 200 mg/day.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.